Sunitinib and Triptorelin: Interaction Details

Brand names
Sunitinib
Sutent
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

Triptorelin

We don't have a drug information page for Triptorelin yet. Have a question about Triptorelin? Ask a pharmacist, free →

What Happens When You Take Sunitinib With Triptorelin

What can happen when they are taken together (rated Major)

Increased risk of

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

When triptorelin is given together with drugs that prolong the , their effects on the QT interval are . GnRH and produce androgen deprivation, which can itself lengthen the QT interval.

In patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities, and in those receiving drugs known to prolong the QT interval, clinicians should weigh whether the benefits of androgen deprivation therapy such as triptorelin exceed the possible risks.1 Where possible, triptorelin should not be combined with QT prolonging agents. If cannot be avoided, drugs that cause electrolyte disturbances (ie, or ) should be avoided,2 any electrolyte abnormalities should be corrected, and periodic and electrolyte monitoring should be considered.1

The Sunitinib and Triptorelin Interaction, Explained

Both of these medicines can affect the heart's electrical rhythm. Sunitinib (Sutent) and triptorelin (a hormone-lowering treatment) can each lengthen something called the , which is a measure on a heart tracing (). Taking them together may add up this effect, which could raise the chance of an abnormal heart rhythm. This concern is based on how the drugs work, not on proven cases.

Please keep taking both as prescribed. Talk with your pharmacist or doctor, especially if you have heart problems or a family history of rhythm problems. Your care team may check your heart tracing and blood salts (like potassium and magnesium) from time to time to keep you safe.

(). Sunitinib is associated with dose-related QT prolongation, and androgen deprivation (GnRH such as triptorelin) may also prolong . Evidence for the combination is theoretical; onset unspecified; severity listed as major. No PK interaction is implied.

  • Avoid when possible; weigh ADT benefit against risk, especially with congenital long QT, heart failure, or recurrent electrolyte disturbances.
  • If coadministration is required: avoid agents causing or , and correct existing electrolyte abnormalities.
  • Consider periodic and electrolyte monitoring.

See the 3 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Sunitinib and Triptorelin Interact

The likely mechanism

In short: Sunitinib and triptorelin both lengthen the QT interval, a measure of the heart’s rhythm, so taken together the effect can add up.
How Drug Interactions Work See this kind of interaction drawn out, step by step, in “When Effects Add Up or Cancel Out”, one chapter of our one-minute explainer. See how it works 

How to Manage the Sunitinib and Triptorelin Interaction

Your care team can manage this by weighing benefits and risks and monitoring you.

  • Keep taking both medicines as prescribed unless your prescriber tells you otherwise.
  • Your team may avoid this pairing when possible, or choose it only if the benefits outweigh the risks.
  • They may check and correct your potassium and magnesium, and may avoid other medicines that lower these.
  • They may consider periodic ECGs and blood tests.

Tell your pharmacist or doctor about any heart conditions, fainting, palpitations, or other medicines you take.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Sunitinib or Triptorelin need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

1 report from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes

    A study of male patients receiving androgen deprivation therapy (ADT) analyzed individual case safety reports from the international pharmacovigilance database VigiBase and identified 184 cases of acquired long-QT syndrome (aLQTS) and/or (TdP; 11% of cases fatal) and 99 cases of sudden death associated with ADT. Most of the aLQTS/TdP cases (62%) and sudden death cases (88%) occurred without exposure to other drugs known to raise TdP risk.

    However, some events involved exposure to 1 drug or to 2 or more drugs with conditional, possible, or known TdP risk (aLQTS/TdP, 23% or 43%; sudden death, 18% and 22%). The drugs classified as ADTs were abiraterone, gonadotropin-releasing hormone and , nonsteroidal androgen receptor indicated for prostate cancer, and 5-alpha-reductase inhibitors indicated for androgenic alopecia and prostatism.

    Of the 10 ADTs assessed, 7 showed a disproportional association (reporting odds ratio, 1.4 to 4.7) with aLQTS, TdP, or sudden death: leuprorelin, goserelin, triptorelin, degarelix, bicalutamide, finasteride, and dutasteride. The median patient age was about 76 years.

    The median time to onset was 170 days (range, 7 to 4884 days) for aLQTS/TdP events and 92 days (range, 0.25 to 4984 days) for sudden death events. Patients were receiving ADT mainly for prostate cancer, and some were treated for prostatism and androgenic alopecia. Most patients were on ADT monotherapy (83%), while 17% were receiving ADT combination therapy.3

Sunitinib and Triptorelin: Common Questions

How serious is the Sunitinib and Triptorelin interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Sunitinib and Triptorelin interaction managed?

Your care team can manage this by weighing benefits and risks and monitoring you. Keep taking both medicines as prescribed unless your prescriber tells you otherwise. Your team may avoid this pairing when possible, or choose it only if the benefits outweigh the risks. They may check and correct your potassium and magnesium, and may avoid other medicines that lower these. They may consider periodic… Management is individual — always follow your own care team's guidance.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

Ask About the Sunitinib and Triptorelin Interaction

Ask in your own words about taking Sunitinib and Triptorelin together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (3)

  1. Product Information: TRELSTAR(R) intramuscular injection suspension, triptorelin pamoate intramuscular injection suspension. Verity Pharmaceuticals Inc (per FDA), Ewing, NJ, 2025.
  2. Lyon AR, Lopez-Fernandez T, Couch LS, et al: 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43(41):4229-4361.
  3. Salem JE, Yang T, Moslehi JJ, et al: Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation 2019; 140(13):1070-1080. PubMed
Was this write-up helpful?

Other Serious Interactions of Sunitinib and Triptorelin

Also serious with Sunitinib

Also serious with Triptorelin

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Sunitinib

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.